AZPCC | AZ Prostate Cancer Coalition

AI-assisted HIFU for Prostate Cancer

Governor Hobbs proclaims September 2024 Arizona Prostate Cancer Awareness Month

Radioactive drugs strike cancer with precision

HRR Testing Underused in mCRPC

Patient Selection for Radioligand Therapy

Plant-Based Diets Tied With Lower Prostate Cancer Progression Risk, Better QOL

BREAKING NEWS: PCF Screening Guidelines for Black Men Now Published

President Biden proclaims April 2024 inaugural National Cancer Prevention and Early Detection Month

Change the Odds initiative to bridge the gap in cancer care disparities

PCF: Know your risk, spread the word

US Dept. of Defense: Early screening is important for detection and treatment of prostate cancer

SMYD3 enzyme role in prostate cancer

HPV infections increase Prostate Cancer risk

New cancer treatment from inside the prostate gland

Personalized dosing improves patient outcomes

FDA approves talazoparib plus enzalutamide for HRR gene–mutated mCRPC

FDA approves new PSMA imaging agent

Important pending Prostate Cancer legislation that can affect you

FDA approves New Jersey Pluvicto Production

IsoPSA could eliminate need for biopsy

NIH declines to force lower priceon Xtandi

Let's support our "sisters" battling Triple-Negative Breast Cancer/BRCA1 mutation

New Cancer Data Spark Outcry From Patient Advocates

Targeting a single enzyme can kill prostate cancer cells

Cedars-Sinai Blood Test Detects and Profiles Prostate Cancer

Advanced Prostate Cancer rates on the rise

ACS's IMPACT initiative focuses on Prostate Cancer in Black men

Metastasis-Directed Therapy beneficial in Oligometastatic Prostate Cancer

Researchers identify new therapeutic approach against treatment-resistant prostate cancer

New genetic test for early detection

Test to Predict Prostate Cancer Agressiveness

Prostate Cancer Markers Help Individualize Care

FDA approves lu177 treatment for men with advanced prostate cancer

Radium-223 w/ Enzalutamide could increase life expectancy in mCRPC

Your best life before, during and after Prostate cancer. Check out the Prostate Cancer Foundation report

The National Alliance of State Prostate Cancer Coalitions (NASPCC) recommends a baseline prostate specific antigen (PSA) blood test and digital rectal exam (DRE) beginning at age 40 (at 35 if high risk, including African-America Men or men with a certain or indeterminate family history of prostate cancer), and then periodically depending on those results. You should know and keep tract of all your PSA measurements and ANY CHANGE IN PSA should be discussed with your doctor.

The Arizona Prostate Cancer Coalition is here to help you navigate through the jargon and maze of treatment options. Check out our services page for links to support groups, upcoming events and more!